CAJ | 학술논문

目的：探讨瑞舒伐他汀和阿托伐他汀对急性心肌梗死患者的疗效、安全性及长期用药的依从性、耐受性。方法120例急性心肌梗死、愿意接受经皮冠状动脉介入术治疗的患者分为瑞舒伐他汀组和阿托伐他汀组，各60例，观察术前和术后6个月总胆固醇（ TC）、三酰甘油（ TG）、低密度脂蛋白胆固醇（ LDL-C）、高密度脂蛋白胆固醇（HDL-C）、超敏C反应蛋白（hs-CRP）、白细胞介素-8（ IL-8）、肿瘤坏死因子-α（ TNF-α）。记录支架内再狭窄率及主要心血管事件发生率。结果瑞舒伐他汀组TC、TG、LDL-C、hs-CRP、IL-8、TNF-α均显著低于阿托伐他汀组（ P ＜0.05）， HDL -C 显著高于阿托伐他汀组（ P ＜0.05），依从性优于阿托伐他汀组（ P＜0.05）。心绞痛发生率显著低于阿托伐他汀组（ P＜0.05）。2组耐受性差异无统计学意义（ P＞0.05）。结论瑞舒伐他汀较阿托伐他汀有更强的调脂和抗炎作用，减少心绞痛及支架再狭窄的发生率，治疗依从性更佳。
목적：탐토서서벌타정화아탁벌타정대급성심기경사환자적료효、안전성급장기용약적의종성、내수성。방법120례급성심기경사、원의접수경피관상동맥개입술치료적환자분위서서벌타정조화아탁벌타정조，각60례，관찰술전화술후6개월총담고순（ TC）、삼선감유（ TG）、저밀도지단백담고순（ LDL-C）、고밀도지단백담고순（HDL-C）、초민C반응단백（hs-CRP）、백세포개소-8（ IL-8）、종류배사인자-α（ TNF-α）。기록지가내재협착솔급주요심혈관사건발생솔。결과서서벌타정조TC、TG、LDL-C、hs-CRP、IL-8、TNF-α균현저저우아탁벌타정조（ P ＜0.05）， HDL -C 현저고우아탁벌타정조（ P ＜0.05），의종성우우아탁벌타정조（ P＜0.05）。심교통발생솔현저저우아탁벌타정조（ P＜0.05）。2조내수성차이무통계학의의（ P＞0.05）。결론서서벌타정교아탁벌타정유경강적조지화항염작용，감소심교통급지가재협착적발생솔，치료의종성경가。
Objective To evaluate the efficacy and safety of rosuvastatin and atorvastatin in acute myocardial infarction ( AMI ) , and its therapy compliance and tolerance of long -time medication.Methods A total of 120 patients with AMI who were willing to receive percutaneous coronary intervention ( PCI) were enrolled and divided into rosuvastatin group ( n=60) and atorvastatin group(n=60).Total cholesterol(TC), triglyceride ( TG ) , low density liporotein -cholesterol ( LDL -C ) , high density lipoprotein cholesterol ( HDL-C) , high-sensitivity C -reactive protein ( hs -CRP ) , interleukin -8 ( IL -8 ) , tumor necrosis factor -α( TNF-α) were observed before and 6 months after surgery. Stent restenosis and major adverse cardiac events ratio were recorded . Results TC, TG, LDL-C, hs-CRP, IL-8, TNF-αin rosuvastatin group was lower than that in atorvastatin group ( P<0.05 ).HDL-C was higher than atorvastatin group ( P<0.05 ) and its compliance was better than atorvastatin group (P<0.05).The incidence of angina was signifi-cantly lower than the atorvastatin group (P<0.05).The tolerance of two groups had no significant difference ( P >0.05 ) .Conclusion Rosu-vastatin has a better lipid and anti-inflammatory effect than atorvastatin . It also can reduce the incidence of stenocardia and restenosis .